When Roche Holding acquired full ownership of Genentech last year the $46.8 billion deal was the culmination of a more than 20-year relationship between the Swiss pharmaceutical giant and the Silicon Valley biotechnology company. In a recent presentation at Wharton San Francisco Steve Krognes -- a former Roche executive who is now senior vice president and CFO of Genentech -- talked about the pharma company’s decision to pursue the merger efforts to raise capital amid the beginnings of the 2008 recession and the aftermath of the deal.
Hosted on Acast. See acast.com/privacy for more information.
Knowledge at Wharton